Atomoxetine Hcl
Brand names: Atomoxetine Hcl, Strattera
At a glance
- Medicare prescriptions, 2024
- 182,076
- Medicare drug cost
- $17.2M
- Average cost per prescription
- $94.45
- Clinicians who prescribed it
- 8,984
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
STRATTERA is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients 6 years of age and older.
From the FDA-approved prescribing information (label dated June 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER All STRATTERA-treated pediatric patients 6 years of age or older should be monitored and observed closely for suicidal thoughts and behavior, clinical worsening, or unusual changes in behavior, especially during the initial months of therapy or at times of dosage changes. Families and caregivers should be advised of the need for close observation and communication with the health care provider. Consider stopping STRATTERA in patients who experience emergent suicidal thoughts and behavior. STRATTERA increased the risk of suicidal ideation in pediatric patients aged 6 years of age and older with attention-deficit/hyperactivity disorder (ADHD) in short-term studies.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Psychiatric Nurse Practitioners 34.9%
- Psychiatry 33.7%
- Nurse Practitioners 10.0%
- Family Medicine 6.3%
- Physician Assistants 5.8%
- Internal Medicine 3.1%
- Child & Adolescent Psychiatry 2.4%
- Neurology 1.8%
- Addiction Medicine 0.4%
- Geriatric Medicine 0.3%
- General Practice 0.3%
- Physical Medicine & Rehabilitation (PM&R) 0.1%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 78% from 2019 to 2024.
Biggest change by state since 2019
- Florida +104%
- North Carolina +97%
- Texas +94%
- Missouri +83%
- Michigan +79%
- Minnesota (smallest change) +49%
- Pennsylvania (smallest change) +51%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Eli Lilly and Company
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | white capsule, 16 mm | LILLY 3227 10 MG |
| 18 mg | yellow capsule, 16 mm | LILLY 3238 18 MG |
| 25 mg | blue capsule, 16 mm | LILLY 3228 25 MG |
| 40 mg | blue capsule, 16 mm | LILLY 3229 40 MG |
| 60 mg | yellow capsule, 18 mm | LILLY 3239 60 MG |
| 80 mg | brown capsule, 18 mm | LILLY 3250 80 MG |
| 100 mg | brown capsule, 20 mm | LILLY 3251 100 MG |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
2 recalls since 2020
- Apr 2026 · Safecor Health, LLC · Class II
Labeling: Label Mix-Up: Atomoxetine HCl 25mg Capsule incorrectly labeled as Atomoxetine HCl 10mg Capsule. - Jan 2025 · Glenmark Pharmaceuticals Inc., USA · Class II
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.